Bavarian Nordic upgrades guidance for second time in five days

Just five days have passed since Bavarian Nordic last upgraded its financial guidance for the year -- but now it is doing so again. The company is the only one with an approved monkeypox vaccine, and demand is soaring.

Photo: Bavarian Nordic / PR

Bavarian Nordic has upgraded its financial guidance for the second time in five days, it reports in a stock exchange notification.

The upgrade is attributed to sales of the company’s monkeypox vaccine. Several countries have placed orders, and Bavarian Nordic states that it is in dialog with more.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs